Active Biotech AB
Research Active Biotech AB (ACTI) on Bullrun: market cap SEK 139.98M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerACTI
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 139.98M
- Financial periodQ1 2026
- RevenueSEK 0
- Net income-SEK 8.40M
- Free cash flow-SEK 8.00M
Valuation Snapshot
latest market cap is SEK 139.98M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 0 | -SEK 37.30M | -SEK 32.40M | n/a | -0.03 | SEK 65.10M | SEK 1.74M | SEK 55.61M |
| FY2024 | SEK 0 | -SEK 39.40M | n/a | n/a | -0.09 | SEK 27.40M | SEK 3.18M | SEK 32.74M |
| FY2023 | SEK 0 | -SEK 45.80M | n/a | n/a | -0.17 | SEK 36.22M | n/a | SEK 30.67M |
| FY2022 | SEK 0 | -SEK 58.37M | n/a | n/a | -0.25 | SEK 41.80M | n/a | SEK 34.51M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | SEK 139.98M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Active Biotech AB
Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Active Biotech AB's market cap?
Active Biotech AB's market capitalization is SEK 139.98M.
What does Active Biotech AB do?
Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors.